2.4 Childhood Exanthems and Oncogenic Viruses: MMR, Varicella, Zoster, and HPV
Key Takeaways
- Measles (Rubeola, Paramyxoviridae) is an airborne viral illness with an R0 of 12–18, characterized by high fever, the '3 Cs' (cough, coryza, conjunctivitis), pathognomonic Koplik spots, cephalocaudal maculopapular rash, and long-term immune amnesia.
- Mumps causes painful parotid swelling and complications including post-pubertal orchitis and aseptic meningitis; Rubella causes mild rash in children but severe Congenital Rubella Syndrome (CRS: deafness, cataracts, cardiac defects) if contracted during pregnancy.
- Varicella-Zoster Virus (VZV) causes primary chickenpox ('dewdrops on a rose petal' rash), establishes latency in dorsal root and cranial sensory ganglia, and can reactivate as Herpes Zoster (shingles) with debilitating postherpetic neuralgia (PHN).
- Shingrix is a non-live recombinant subunit vaccine (glycoprotein E + AS01B adjuvant) administered as a 2-dose IM series for all immunocompetent adults aged 50+ and immunocompromised adults aged 19+, regardless of prior chickenpox, shingles, or live Zostavax vaccination.
- Human Papillomavirus (HPV) high-risk types 16 and 18 drive oncogenesis via E6 (p53 degradation) and E7 (pRb inactivation) oncoproteins; Gardasil 9 is administered in a 2-dose series if started before age 15 (0, 6–12 months) or a 3-dose series (0, 1–2, 6 months) for individuals aged 15–26.
Last updated: August 2026
2.4 Childhood Exanthems and Oncogenic Viruses: MMR, Varicella, Zoster, and HPV
Childhood viral exanthems and oncogenic viruses represent critical targets of national immunization programs. From highly infectious paramyxoviruses that induce prolonged immune amnesia to persistent herpesviruses establishing lifelong neural latency and oncogenic papillomaviruses driving epithelial carcinomas, pharmacy technicians must master the underlying pathophysiology, clinical presentations, and vaccine mechanics.
1. Measles, Mumps, and Rubella (MMR)
+-----------------------------------------------------------------------------+
| MEASLES (RUBEOLA) PATHOLOGY |
| |
| • Viral Family: Paramyxoviridae (enveloped negative-sense ssRNA) |
| • Transmission: Airborne aerosol droplets (R0 = 12 to 18) |
| - Virions remain suspended and infectious in airborne space for > 2 hrs |
| • Incubation Period: 7–21 days (average 10–14 days) |
| │ |
| ▼ |
| [ PRODROMAL STAGE ] (Lasts 2 to 4 days) |
| - Stepwise escalating high fever (often ≥ 104°F / 40°C) |
| - CLASSIC TRIAD OF THE '3 Cs': |
| 1. COUGH (severe, nonproductive, brassy) |
| 2. CORYZA (profuse clear rhinorrhea, sneezing) |
| 3. CONJUNCTIVITIS (marked photophobia, lacrimation, palpebral edema) |
| - KOPLIK SPOTS: Pathognomonic enanthem appearing 1–2 days BEFORE rash; |
| clustered 1–2 mm bluish-white granular lesions on an erythematous base |
| on the buccal mucosa opposite the lower molars ("grains of salt") |
| │ |
| ▼ |
| [ EXANTHEM STAGE ] |
| - Confluent, erythematous, maculopapular rash |
| - CEPHALOCAUDAL SPREAD: Begins at the hairline and behind ears, spreads |
| downward over face, neck, trunk, and extremities (involves palms/soles) |
| - Rash fades in the same order of appearance, leaving brownish desquamation|
| │ |
| ▼ |
| [ IMMUNE AMNESIA & COMPLICATIONS ] |
| - Destroys memory B and T lymphocytes, causing immunological amnesia for |
| months to years, predisposing to secondary fatal infections |
| - Acute Otitis Media (most common complication, ~1 in 10) |
| - Giant-Cell Bronchopneumonia (leading cause of measles mortality) |
| - Acute Disseminated Encephalomyelitis (ADEM, 1 in 1,000) |
| - Subacute Sclerosing Panencephalitis (SSPE): Rare, fatal, progressive |
| neurodegenerative disease occurring 7–10 years post-infection (1:10,000)|
+-----------------------------------------------------------------------------+
Mumps (Rubulavirus)
- Microbiology: Enveloped negative-sense single-stranded RNA virus of the family Paramyxoviridae.
- Pathogenesis: Transmitted via respiratory droplets and direct saliva contact. Viral entry into the upper respiratory tract is followed by local replication and viremic dissemination to glandular and neural tissues.
- Clinical Manifestations: Prodromal low-grade fever, malaise, and anorexia, followed rapidly by tender, painful swelling of the salivary glands—predominantly parotitis (unilateral or bilateral parotid gland enlargement in 70%–80% of cases, obscuring the angle of the mandible).
- Complications:
- Epididymo-Orchitis: Occurs in 15%–30% of post-pubertal males; painful unilateral or bilateral testicular swelling; causes testicular atrophy in 50% of affected cases (sterility is rare).
- Aseptic Meningitis / Encephalitis: Occurs in up to 10% of cases.
- Sensorineural Hearing Loss: Usually unilateral and permanent due to cochlear endolymphatic labyrinthitis.
- Acute Pancreatitis: Epigastric abdominal pain and elevated lipase/amylase.
Rubella (German Measles / "3-Day Measles")
- Microbiology: Enveloped positive-sense single-stranded RNA virus of the family Togaviridae (genus Rubivirus).
- Clinical Presentation: Mild illness in children characterized by low-grade fever, prominent postauricular, suboccipital, and posterior cervical lymphadenopathy, followed by an evanescent pink, non-confluent maculopapular rash spreading cephalocaudally and resolving within 3 days. Petechial lesions on the soft palate (Forchheimer spots) may be observed.
- Congenital Rubella Syndrome (CRS): The paramount danger of rubella is transplacental teratogenicity when contracted by a non-immune woman during the first trimester of pregnancy (up to 85% risk of severe fetal damage). CRS manifestations include:
- Sensorineural Deafness (most common, ~60%)
- Ocular Defects: Congenital cataracts, microphthalmia, infantile glaucoma
- Congenital Heart Defects: Patent ductus arteriosus (PDA), pulmonary artery stenosis
- Central Nervous System Damage: Microcephaly, developmental delay
- Neonatal Systemic Signs: Hepatosplenomegaly, thrombocytopenic purpura ("blueberry muffin" rash due to extramedullary dermal hematopoiesis)
MMR / MMRV Vaccine Guidelines
- Formulations: M-M-R II / Priorix (live attenuated trivalent MMR); ProQuad (quadrivalent MMRV, approved for ages 12 months through 12 years).
- Routine Schedule: 2-dose series: Dose 1 at 12–15 months, Dose 2 at 4–6 years (prior to school entry).
- Safety & Contraindications: Because MMR is a live attenuated vaccine, it is strictly contraindicated in pregnancy (women should avoid becoming pregnant for 28 days following vaccination) and in severely immunocompromised individuals (e.g., severe primary immunodeficiency, advanced HIV with CD4+ count < 200 cells/mm³, high-dose systemic immunosuppressive therapy).
2. Varicella-Zoster Virus (VZV): Primary Varicella and Herpes Zoster
Varicella-Zoster Virus (Human Alphaherpesvirus 3) is an enveloped, double-stranded DNA virus of the family Herpesviridae. It causes two distinct clinical disease entities:
+-----------------------------------------------------------------------------+
| VZV LIFE CYCLE & CLINICAL DUALITY |
| |
| [ PRIMARY INFECTION: VARICELLA (CHICKENPOX) ] |
| - Transmitted via airborne droplets & direct contact with vesicle fluid |
| - Highly contagious (R0 = 10 to 12) |
| - Incubation: 10–21 days (average 14–16 days) |
| - Hallmark Exanthem: Pruritic macules -> papules -> vesicles on an |
| erythematous base ("dewdrops on a rose petal") -> pustules -> crusts. |
| - Successive crops erupt over 3–5 days: ALL STAGES OF LESIONS PRESENT |
| SIMULTANEOUSLY across the body (primarily central/trunk -> face/limbs) |
| │ |
| ▼ |
| [ RETROGRADE NEURAL RETRO-AXONAL TRANSPORT & LATENCY ] |
| - Following primary infection, virions travel retrogradely up sensory |
| axons to establish lifelong LATENT INFECTION in cranial nerve ganglia |
| and DORSAL ROOT SENSORY GANGLIA |
| │ |
| ▼ (Triggered by aging, stress, immunosuppression)|
| [ REACTIVATION: HERPES ZOSTER (SHINGLES) ] |
| - Virus replicates in sensory ganglion, causing intense ganglionitis and |
| neuronal necrosis, then migrates anterogradely down sensory nerve fibers|
| - Unilateral, dermatomal vesicular eruption that DOES NOT cross midline |
| - Preceded by prodromal burning, shooting, lancinating neuropathic pain |
| - Thoracic (T3–L2) and Trigeminal (V1 ophthalmic branch) most common |
| │ |
| ▼ |
| [ COMPLICATIONS OF ZOSTER ] |
| - POSTHERPETIC NEURALGIA (PHN): Severe, debilitating neuropathic pain |
| persisting for > 90 days following rash resolution (affects ~20% > 50) |
| - Herpes Zoster Ophthalmicus (HZO): V1 trigeminal nerve involvement |
| (Hutchinson's sign on nasal tip); risk of corneal keratitis and blindness|
| - Ramsay Hunt Syndrome: Cranial nerve VII/VIII involvement (facial palsy, |
| auditory canal vesicles, severe sensorineural hearing loss, vertigo) |
+-----------------------------------------------------------------------------+
Varicella and Zoster Vaccine Formulations
+---------------------------------------------------------------------------------------------------+
| VARICELLA (VARIVAX) VS. ZOSTER (SHINGRIX) VACCINES |
| |
| FEATURE VARIVAX (VARICELLA VACCINE) SHINGRIX (RECOMBINANT ZOSTER) |
| ────────────────────── ─────────────────────────────── ───────────────────────────── |
| Platform LIVE ATTENUATED VIRUS (Oka strain) RECOMBINANT SUBUNIT (NON-LIVE) |
| Target Antigen Whole attenuated live VZV VZV Glycoprotein E (gE) antigen |
| Adjuvant None AS01B Adjuvant System (QS-21 + MPL) |
| Administration Route SUBCUTANEOUS (SC) injection INTRAMUSCULAR (IM) injection |
| Target Indication Prevention of PRIMARY chickenpox Prevention of ZOSTER & PHN |
| Routine Schedule 2 doses: 12–15 mos and 4–6 yrs 2 doses: Separated by 2–6 months |
| Approved Age Ages ≥ 12 months Adults ≥ 50 yrs & Immunocompromised |
| adults aged ≥ 19 yrs |
| Pregnancy / Immunodef. CONTRAINDICATED (Live vaccine) PERMITTED (Recombinant non-live) |
+---------------------------------------------------------------------------------------------------+
[!IMPORTANT] Shingrix Clinical Pearls for Pharmacy Practice:
- Shingrix is a non-live recombinant subunit vaccine; it completely replaced the older live attenuated Zostavax (which was discontinued in 2020).
- Administer 2 doses intramuscularly separated by 2 to 6 months.
- Recommended for all immunocompetent adults aged 50 years and older, and all immunocompromised adults aged 19 years and older.
- Administer Shingrix regardless of whether the patient reports a prior history of chickenpox, has had prior episodes of herpes zoster, or previously received the older live Zostavax vaccine.
3. Human Papillomavirus (HPV) and Viral Oncogenesis
Human Papillomavirus is a small, non-enveloped, double-stranded circular DNA virus belonging to the family Papillomaviridae. Over 200 distinct HPV genotypes infect cutaneous and mucosal stratified squamous epithelium.
Low-Risk vs. High-Risk Genotypes and Pathogenesis
- Low-Risk Genotypes (HPV Types 6 and 11): Do NOT integrate into host DNA. Responsible for > 90% of Condylomata Acuminata (benign anogenital warts) and recurrent respiratory papillomatosis (RRP).
- High-Risk Oncogenic Genotypes (HPV Types 16, 18, 31, 33, 45, 52, 58): Responsible for malignant cellular transformation. Types 16 and 18 cause approximately 70% of all cervical carcinomas and an even higher percentage of HPV-attributable anal, vulvar, vaginal, penile, and oropharyngeal carcinomas (especially lingual and palatine tonsillar cancers).
+-----------------------------------------------------------------------------+
| HPV ONCOGENESIS MOLECULAR MECHANISM |
| |
| [ High-Risk HPV Infects Basal Keratinocytes via Microabrasions ] |
| │ |
| ▼ |
| [ Integration of Viral Genome into Host Chromosomal DNA ] |
| - Disrupts viral E2 repressor gene, leading to over-transcription of |
| oncoproteins E6 and E7 |
| │ |
| ┌────────────────┴────────────────┐ |
| ▼ ▼ |
| [ ONCOPROTEIN E6 ] [ ONCOPROTEIN E7 ] |
| - Recruits E6AP ubiquitin ligase - Binds Retinoblastoma Protein (pRb) |
| - Degrades Tumor Suppressor P53 - Displaces E2F Transcription Factor |
| - Prevents apoptotic arrest of - Drives uncontrolled G1 -> S phase |
| damaged host cells cell cycle progression |
| │ │ |
| └────────────────┬────────────────┘ |
| ▼ |
| [ PROGRESSION TO HIGH-GRADE DYSPLASIA & INVASIVE CARCINOMA ] |
+-----------------------------------------------------------------------------+
Gardasil 9 (9-Valent HPV Recombinant Vaccine)
- Composition: Recombinant Virus-Like Particles (VLPs) formed by the L1 major capsid protein of HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, expressed in Saccharomyces cerevisiae (yeast) and adjuvanted with amorphous aluminum hydroxyphosphate sulfate (AAHS).
- Route: Intramuscular (IM) injection.
ACIP Age-Stratified HPV Dosing Schedules
+---------------------------------------------------------------------------------------------------+
| HPV (GARDASIL 9) DOSING ALGORITHM |
| |
| AGE OF INITIATION DOSING SCHEDULE MINIMUM INTERVALS |
| ───────────────── ─────────────── ───────────────── |
| Ages 9 through 14 yrs 2-DOSE SERIES Dose 1: Month 0 |
| (Routine: 11–12 yrs) (0, 6–12 months) Dose 2: 6–12 months after Dose 1 |
| (Absolute minimum: 5 months) |
| |
| Ages 15 through 26 yrs 3-DOSE SERIES Dose 1: Month 0 |
| (Catch-up) (0, 1–2, 6 months) Dose 2: 1–2 months after Dose 1 |
| Dose 3: 6 months after Dose 1 |
| (Min: D1-D2: 4 wks; D2-D3: 12 wks; |
| D1-D3: 5 months) |
| |
| Immunocompromised 3-DOSE SERIES Always 3 doses regardless of age |
| (Any age 9–26 yrs) (0, 1–2, 6 months) at initiation (0, 1–2, 6 months) |
| |
| Adults 27 through 45 yrs SHARED CLINICAL DECISION-MAKING 3-dose series if patient decides to |
| (Individual risk-benefit review) proceed (0, 1–2, 6 months) |
+---------------------------------------------------------------------------------------------------+
Loading diagram...
Test Your Knowledge
A 12-year-old child presents to the pharmacy clinic with a parent to receive their first dose of the Human Papillomavirus (HPV) vaccine. Which dosing schedule and administration parameters should the pharmacy technician prepare under ACIP guidelines?
A
B
C
D
Test Your Knowledge
A 54-year-old immunocompetent patient mentions that he received the live Zostavax vaccine 8 years ago. He asks if he needs the newer Shingrix vaccine. What is the correct clinical recommendation according to ACIP guidelines?
A
B
C
D
Test Your Knowledge
A 5-year-old unimmunized child presents with a 3-day history of escalating high fever (103.8°F), nonproductive brassy cough, profuse coryza, and marked photophobia. Physical examination of the oral cavity reveals tiny, irregular bluish-white spots surrounded by red halos on the buccal mucosa opposite the molars. What viral disease and clinical hallmark are described?
A
B
C
D